Orantinib is an oral small molecule inhibitor inhibiting multiple tyrosine kinase receptors: VEGFR-2, FGFR, and PDGFR in advanced HCC patients (Table 1) [139]. The gene discussed is KDR; the disease is hepatocellular carcinoma.